Ependymal cells-CSF flow regulates stress-induced depression
Ji-Seon Seo1,2, Ioannis Mantas3, Per Svenningsson3
1Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY, USA. jiseon.seo@ki.se.
Molecular Psychiatry
|July 8, 2021
Summary
Reduced p11 protein in brain cells disrupts cerebrospinal fluid (CSF) flow, leading to depression and anxiety. Restoring p11 levels in ependymal cells can reverse these mood disorder symptoms.
Area of Science:
- Neuroscience
- Molecular Biology
- Psychiatry
Background:
- Aberrant cerebrospinal fluid (CSF) circulation is indirectly linked to neurological, neurodegenerative, and psychiatric disorders, including depression.
- Ependymal cells lining the brain ventricles play a crucial role in CSF production and flow.
Purpose of the Study:
- To investigate the role of the p11 protein in ependymal cells and its potential link to major depressive disorder (MDD).
- To explore p11 as a molecular determinant for CSF flow and its impact on mood regulation.
Main Methods:
- Quantification of p11 protein levels in ependymal cells from MDD patients and mouse models of depression.
- Assessment of ependymal cell planar cell polarity (PCP) and CSF flow dynamics.
- Behavioral testing in mouse models to evaluate depression-like and anxiety-like behaviors.
- Viral-mediated gene expression to restore p11 levels in ependymal cells.
Main Results:
- Significantly decreased p11 concentration was observed in ependymal cells of MDD patients and chronic stress-induced mouse models.
- Loss of p11 led to disoriented ependymal PCP, reduced CSF flow, and depression- and anxiety-like behaviors.
- Viral restoration of p11 in ependymal cells successfully rescued the observed pathophysiological and behavioral deficits.
Conclusions:
- p11 is a key molecular determinant regulating ependymal cell function and CSF flow, crucial for mood regulation.
- Dysfunctional CSF flow due to p11 deficiency contributes to depression and anxiety.
- Targeting p11 in ependymal cells offers a novel therapeutic strategy for stress-associated mood and neurological disorders.


